MEIP Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:56):

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...

Stats
Tagesvolumen	9 029.00
Durchschnittsvolumen	21 096.00
Marktkapitalisierung	20.52M
EPS	$0 ( 2024-02-08 )
Nächstes Ertragsdatum	( $-1.520 ) 2024-05-09
Last Dividend	$1.750 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	1.030
ATR14	$0.0330 (1.07%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Flynn James P	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Flynn James P	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
93.08
Last 96 transactions
Buy: 9 932 993 \| Sell: 849 643

MEI Pharma Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

MEI Pharma Inc Finanzdaten

Annual	2023
Umsatz:	$48.82M
Bruttogewinn:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2023
Umsatz:	$48.82M
Bruttogewinn:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2022
Umsatz:	$40.70M
Bruttogewinn:	$39.46M (96.97 %)
EPS:	$-8.80

FY	2021
Umsatz:	$25.54M
Bruttogewinn:	$24.13M (94.49 %)
EPS:	$-0.450

Financial Reports:

No articles found.

MEI Pharma Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

MEI Pharma Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.51 - average (50.95%) | Divividend Growth Potential Score: 0 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.750	2023-11-16
Last Dividend	$1.750	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.750	--
Avg. Dividend % Per Year	11.67%	--
Score	4.75	--
Div. Sustainability Score	5.51
Div.Growth Potential Score	0
Div. Directional Score	2.48	--

Next Divdend (Est)
(2024-04-29)

$3.50 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.75

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.750	35.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.286	1.500	4.27	6.41	[0 - 0.5]
returnOnAssetsTTM	0.265	1.200	1.173	1.408	[0 - 0.3]
returnOnEquityTTM	0.416	1.500	6.49	9.73	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.23	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.644	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.153	-1.500	7.45	-10.00	[0 - 0.6]
interestCoverageTTM	-16.44	1.000	-7.20	-7.20	[3 - 30]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
freeCashFlowPerShareTTM	-7.95	2.00	-3.97	-7.95	[0 - 20]
debtEquityRatioTTM	0.202	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.980	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.63	7.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.40	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.925	0.800	7.17	5.73	[0.5 - 2]
Total Score				5.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.977	1.000	-0.00231	0	[1 - 100]
returnOnEquityTTM	0.416	2.50	7.74	9.73	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.95	2.00	-2.65	-7.95	[0 - 30]
dividendYielPercentageTTM	114.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.729	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-0.560

MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.